You are viewing a free preview of this lesson.
Subscribe to unlock all 10 lessons in this course and every other course on LearningBro.
Sophisticated synthesis planning is the capstone of A-Level organic chemistry: not the memorisation of any single reaction, but the orchestration of many reactions in sequence to build a target molecule from simple, commercially available starting materials. This lesson develops three threads. First, multi-step synthesis — how to combine the reactions from earlier courses (foundations and the first eight lessons of this advanced course) into routes of three, four, or five steps, tracking functional groups and stereochemistry at every transformation. Second, asymmetric (enantioselective) catalysis — the methods used in modern industry to produce a single enantiomer of a chiral target rather than a wasteful 50:50 racemate, including the Sharpless, Noyori and Knowles approaches recognised by the 2001 Nobel Prize, plus chiral pool synthesis. Third, protecting groups — the temporary masking of reactive functional groups so that incompatible chemistry can be performed elsewhere in the molecule. Together these themes turn organic chemistry from a list of arrows into a strategic discipline.
Spec mapping (AQA 7405): This lesson anchors §3.3.14 (organic synthesis) and pulls forward content from lesson 2 (esters and amides, §3.3.9), lesson 5 (amines, §3.3.11), lesson 6 (amino acids, §3.3.12), and lesson 8 (synthesis pathways foundations, §3.3.14). It also draws on the organic mechanisms master class lesson 8 of the foundations course (functional-group interconversion). Refer to the official AQA specification document for exact wording.
Assessment objectives: AO1 covers recall of the purpose of asymmetric synthesis, the chiral pool concept, and the role of protecting groups. AO2 dominates Paper 3 questions on multi-step route design: students must devise three- to five-step sequences from a named starting material to a named target and predict stereochemical outcomes at each step. AO3 features in evaluative questions — comparing alternative routes for stereochemistry, yield and atom economy, and predicting the effect of switching from a Lewis-acid catalyst to a chiral metal complex.
A multi-step synthesis is a planned sequence of reactions taking a commercially available starting material through one or more isolable intermediates to a defined target compound. The planning question is always the same: what functional group is present, what functional group is required, and which reaction interconverts them? Every reaction encountered in the foundations and advanced courses is a tool; the synthetic chemist's skill is in choosing the right tool in the right order.
A useful planning heuristic is retrosynthesis — working backwards from the target. Identify the functional group in the target, identify a reaction that produces that functional group, and write the immediate precursor. Repeat until the precursor is a commercial starting material. The forward route is then the reverse of this backward analysis, with reagents and conditions specified at each arrow.
At every step three things must be tracked: (i) the functional group present and how it is being transformed; (ii) the carbon skeleton — is the chain being lengthened (nitrile, Grignard, Friedel-Crafts), shortened (decarboxylation, haloform) or unchanged (substitution, oxidation, reduction)?; and (iii) the stereochemistry — does the step generate, preserve or destroy a chiral centre? Forgetting any of these three is the single most common cause of lost marks on Paper 3 synthesis questions.
Aspirin (acetylsalicylic acid, 2-acetoxybenzoic acid) is synthesised industrially in a single step by acylation of the phenolic –OH of salicylic acid with ethanoic anhydride.
Salicylic acid + ethanoic anhydride → aspirin + ethanoic acid
Conditions: catalytic concentrated H₂SO₄ or H₃PO₄, gentle warming (~50 °C) for ~15 minutes. The phenolic –OH attacks the carbonyl of the anhydride; tetrahedral intermediate collapse expels ethanoate as the leaving group; aspirin and ethanoic acid are produced in a 1:1 ratio. Yields are routinely 70–85% on the school scale; recrystallisation from hot water gives a white crystalline solid (m.p. 138–140 °C). This is the classic A-Level required-practical-style synthesis: a single C–O bond is formed, no stereochemistry is generated (aspirin has no chiral centres), and product identity is confirmed by melting point and IR (loss of the broad O–H stretch of the phenol; appearance of two distinct C=O stretches at ~1750 and ~1690 cm⁻¹).
Paracetamol (4-acetamidophenol) is a four-step synthesis from phenol. It illustrates electrophilic aromatic substitution, reduction, and amide formation in a single route.
Step 1 — Nitration. Phenol + concentrated HNO₃ (dilute, ~20%) at 5 °C → 4-nitrophenol (major) + 2-nitrophenol (minor). The –OH activates the ring and directs ortho/para; the para isomer is isolated by steam distillation (the ortho isomer is volatile and distils first; the para isomer is non-volatile and remains).
Step 2 — Reduction. 4-nitrophenol + Sn / concentrated HCl (or H₂ / Ni catalyst at elevated pressure) → 4-aminophenol. The nitro –NO₂ group is reduced to an amine –NH₂. In industry the catalytic hydrogenation route is preferred (atom-economical, no metal-salt waste).
Step 3 — Acylation. 4-aminophenol + ethanoic anhydride → 4-acetamidophenol (paracetamol) + ethanoic acid. The aromatic –NH₂ is more nucleophilic than the phenolic –OH, so under controlled conditions (slight excess of amine, no acid catalyst) the amide forms selectively without esterification of the phenol. Conditions: gentle warming in dilute aqueous solution, ~30 minutes.
Step 4 — Purification. Recrystallisation from hot water gives pure paracetamol as white crystals (m.p. 169–172 °C). Overall yield over the three productive steps is typically 30–45% on the school scale; industrially, 80–85% per step is achievable, giving an overall yield around 50–60%.
This route shows three key skills: electrophilic aromatic substitution with regiochemical control (step 1), functional-group interconversion by reduction (step 2), and chemoselective acylation of an amine over a phenol (step 3).
Ibuprofen is synthesised industrially via the BHC / Hoechst-Celanese route, a three-step process that replaced an earlier six-step Boots synthesis in 1991. The first step is a Friedel-Crafts acylation of isobutylbenzene with ethanoic anhydride catalysed by HF (or AlCl₃ in older variants) to give 1-(4-isobutylphenyl)ethanone. The second step is a hydrogenation of the ketone to the corresponding alcohol with Raney nickel under H₂. The third step is a palladium-catalysed carbonylation with CO that installs the carboxylic acid group, giving ibuprofen directly. The overall atom economy is around 80%, compared to ~40% for the original Boots route — a significant green-chemistry improvement that won the Presidential Green Chemistry Challenge Award. At A-Level you would not be expected to draw the full mechanism, but you should recognise the Friedel-Crafts acylation (lesson 4) as the carbon–carbon bond-forming step, and appreciate that the catalytic carbonylation replaced a multi-step Grignard/oxidation sequence.
Caprolactam — the cyclic amide monomer of nylon-6 — is produced industrially from cyclohexanol in three steps. (i) Cyclohexanol is oxidised to cyclohexanone with air over a copper catalyst (or with chromium reagents on the laboratory scale). (ii) Cyclohexanone is converted to its oxime by reaction with hydroxylamine (NH₂OH). (iii) The oxime undergoes the Beckmann rearrangement in concentrated H₂SO₄: the C–C bond anti to the OH migrates onto the nitrogen, expanding the six-membered carbocycle into a seven-membered lactam (cyclic amide), caprolactam. Ring-opening polymerisation of caprolactam with water at ~250 °C gives nylon-6, a polyamide of repeating –NH–(CH₂)₅–CO– units. At A-Level you should recognise this as a worked example of the link between cycloalkane chemistry, oxime formation, and condensation polymer synthesis (lesson 7); the Beckmann rearrangement itself is beyond the specification and is signposted only.
A core challenge in synthesis is that most A-Level reactions which generate a chiral centre from an achiral starting material produce a racemate — a 50:50 mixture of the two enantiomers. Two canonical examples:
HCN addition to propanal. Propanal (CH₃CH₂CHO) is planar at the carbonyl carbon. CN⁻ attacks from either face with equal probability, giving 50% (R)-2-hydroxybutanenitrile and 50% (S)-2-hydroxybutanenitrile. The product is optically inactive (zero rotation) because the two enantiomers rotate plane-polarised light by equal and opposite amounts.
SN1 hydrolysis of (R)-2-bromobutane. Loss of bromide gives a planar carbocation intermediate. Water attacks from either face with equal probability, giving racemic 2-butanol. The stereochemistry of the starting material is destroyed by passing through an achiral (planar) intermediate.
A racemic product is a problem when only one enantiomer is the desired pharmaceutical or fragrance — the other enantiomer is at best inactive (a 50% atom-economy penalty) and at worst harmful. The four asymmetric-synthesis strategies below address this directly.
Start from a naturally occurring chiral starting material — one whose enantiomeric purity is given for free by biology. Examples include the proteinogenic L-amino acids (alanine, valine, proline, etc.), the D-sugars (glucose, fructose, ribose), the terpenes ((R)-limonene, (S)-carvone, menthol), and natural alkaloids (quinine, cinchonidine). The route is designed so that the stereocentre of the natural product becomes the stereocentre of the target. This approach is cheap (nature does the asymmetric step) but limited: the target's stereochemistry is dictated by what nature provides, and the synthesis is restricted to molecules structurally close to the natural starting material.
A chiral group is temporarily attached to a reagent, the reaction is performed stereoselectively in the presence of this auxiliary, and the auxiliary is removed after the new stereocentre is set. The auxiliary is recovered, often quantitatively, for reuse. Evans's chiral oxazolidinones (derived from L-phenylalanine) are the canonical example. This is a three-step procedure (attach – react – cleave), so each new stereocentre costs two operations, but it gives reliable, near-perfect stereoselection. The downside is the two extra steps reduce overall yield.
A small amount (often 0.1–10 mol%) of a chiral catalyst directs the reaction so that one enantiomer of the product is formed preferentially. Three landmark examples — recognised together by the 2001 Nobel Prize in Chemistry — are summarised below.
In each case the catalyst is the only chiral species in the reaction; the product chirality is induced by the catalyst, not transferred from a stoichiometric chiral reagent. A small amount of catalyst can produce enantiopure product in tonne quantities — this is the central efficiency of asymmetric catalysis.
Enzymes are nature's chiral catalysts: every enzyme active site is intrinsically asymmetric because it is built from L-amino acids. Industrial enzymes (lipases, esterases, dehydrogenases, transaminases) are used widely for asymmetric ester hydrolysis (kinetic resolution of racemic esters by hydrolysis of only one enantiomer), asymmetric ketone reduction (giving enantiopure alcohols), and asymmetric C–N bond formation (transaminases producing chiral amines). The selectivity is often near-perfect (ee > 99%), the conditions are mild (water, 25–40 °C, atmospheric pressure), and the catalyst is biodegradable. Modern protein engineering has dramatically expanded the substrate scope of these enzymes (see Going Further).
Many natural and synthetic chiral compounds have biological activity that depends on the absolute configuration of the molecule. Enzymes, receptors and antibodies are themselves chiral, so they bind one enantiomer of a substrate or drug far more tightly than the other.
The historical reference point is thalidomide, sold as a racemic sedative in the late 1950s and early 1960s. Subsequent investigation linked the (S)-enantiomer to teratogenic effects in pregnancy; the (R)-enantiomer was the intended sedative. Even single-enantiomer thalidomide is now known to racemise in vivo, so the historical lesson is not "always sell single enantiomers" but "always evaluate both enantiomers separately for biological activity, and characterise their interconversion in physiological conditions". The regulatory framework for chiral pharmaceuticals (the FDA's 1992 policy and equivalents elsewhere) is the modern outcome.
A second example you should know factually: ibuprofen. The (S)-enantiomer is the active analgesic and anti-inflammatory; the (R)-enantiomer is biologically inactive, but is slowly converted to the (S)-form in vivo by an isomerase enzyme. Ibuprofen is sold as the racemate (manufacturing the racemate is much cheaper, and the body performs the asymmetric conversion). This is the opposite design choice to a target like L-DOPA, where the (R)-enantiomer is not converted and would be ballast.
Similar enantiomer-dependent effects are seen in pesticides (one enantiomer often insecticidal, the other inactive or environmentally persistent) and fragrances (the two enantiomers of carvone smell of caraway and spearmint respectively — same atoms, different odours, because olfactory receptors are chiral).
If a racemic mixture is unavoidable, the two enantiomers can be separated by resolution. The classical method:
Resolution gives both enantiomers, but if only one is wanted the other half of the material is wasted unless it can be racemised and recycled. The atom-economy penalty is severe — up to 50% of the input is discarded — which is why asymmetric synthesis is preferred wherever it is feasible.
A protecting group is a temporary chemical modification of a reactive functional group that renders it inert to the reaction conditions of a subsequent step. After the reactive chemistry is complete, the protecting group is removed (deprotected) to restore the original functional group. Three examples used at A-Level depth:
Every protection–deprotection pair adds two steps to the synthesis, with two associated yield penalties. A well-planned route minimises protecting-group manipulations; a poorly planned route can spend more steps on protections than on the productive bond-forming chemistry.
Overall yield is the product of individual step yields. For a three-step synthesis with yields of 80%, 70% and 85%:
Overall yield = 0.80 × 0.70 × 0.85 = 0.476 = 47.6%.
For a five-step synthesis where each step gives 80%:
Overall yield = 0.80⁵ = 0.328 = 32.8%.
For a ten-step synthesis at 80% per step: 0.80¹⁰ = 10.7%. The product yield falls geometrically with step count, so a fundamental design principle is: minimise the number of steps. A two-step route with 60% per step (overall 36%) is often preferable to a five-step route with 80% per step (overall 33%), and far preferable to a five-step route with 70% per step (overall 17%).
This is the quantitative justification for retrosynthesis (find the shortest route to the target), for convergent synthesis (combine two halves of the molecule late in the sequence rather than building linearly from one end), and for telescoping reactions (carrying an intermediate forward to the next step without isolation, eliminating the yield penalty of purification).
Subscribe to continue reading
Get full access to this lesson and all 10 lessons in this course.